Background: Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of NO synthesis. ADMA is degraded by dimethylarginine dimethylaminohydrolase (DDAH).We and others have previously shown that NO synthesis is required for normal angiogenesis, which is impaired by ADMA. Methods: To determine if the effects of ADMA on angiogenesis could be reversed by overexpression of DDAH, we used DDAH 1 transgenic (TG) mice and wildytpe (WT) littermates (each n=42) and employed the disk angiogenesis system (DAS) as well as a murine model of hindlimb ischemia. Post surgery animals were treated with either PBS, or the NOS inhibitors ADMA or N ω -nitro-L-arginine methyl ester (L-NAME; each 250µmol/kg/day) using osmotic minipumps. L-NAME is an exogenous NOS inhibitor that is not degraded by DDAH. Results: Neovascularization in the DAS was significantly impaired by both NOS inhibitors. However, the TG animals were resistant to the effects of ADMA and manifested greater neovascularization. The angiogenic response(capillary density) to hindlimb ischemia was enhanced in TG mice. In addition, TG mice were resistant to the effects of ADMA on angiogenesis or arteriogenesis (collateral growth) which were impaired significantly by ADMA in WT animals. These findings were confirmed by measuring hindlimb perfusion using fluorescent microspheres. Enhanced neovascularization and limb perfusion in the TG mice were associated with reduced plasma and tissue ADMA levels and enhanced tissue NOS enzyme activity. Conclusion: Overexpression of the enzyme DDAH reduces levels of the endogenous NOS inhibitor ADMA, thereby increasing NO synthesis, and enhancing angiogenesis and arteriogenesis. Therapeutic manipulation of DDAH expression or activity may represent a novel approach to restoring tissue perfusion. Background: Type II diabetes mellitus (DM) is increasing worldwide. Therefore approaches to prevent DM in patients who are at high risk, (such as those with hypertension and cardio-vascular disease) are needed. Previous analyses have indicated that inhibiting the renin-angiotensin-aldosterone system (RAAS) can reduce the incidence of DM. In the CHARM-programme we investigated whether the angiotensin receptor blocker candesartan reduces mortality and morbidity and in addition the incidence of DM in a broad population of patients with symptomatic chronic heart failure (CHF 
Conclusion:
In addition to reducing cardiovascular morbidity and mortality in chronic heart failure, candesartan also reduces the risk of development of diabetes mellitus.
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810-2 Effects of Growth Hormone on Circulating Cytokine Dysbalance and Left Ventricular Geometry in Patients With Idiopathic Dilated Cardiomyopathy
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Background: Experimental studies have demonstrated that growth hormone (GH) can influence left ventricular (LV) myocardial growth and remodeling in the setting of chronic heart failure (CHF). This study investigates whether the effects of GH on LV geometry are associated with the respective modulation of circulating proinflammatory /anti-inflammatory cytokine balance in patients with CHF secondary to idiopathic dilated cardiomyopathy (IDC). Methods: Plasma proinflammatory cytokines TNF-a, IL-6, MCP-1 and anti-inflammatory molecules IL-10 and TGF-b2 were measured (ELISA) in 12 IDC patients (NYHA class III; LVEF: 23.6±1.7%) before and after a 3-month subcutaneous administration of GH 4IU every other day (randomized crossover design). Peak oxygen uptake (VO2max), LV dimensions, volumes and mass index (LVMI) were determined at the same period. Results: A significant decrease of plasma cytokines TNF-a (7.8±1.1 vs 5.5±0.9 pg/ml, p<0.02), IL-6 (5.7±vs 4.7±0.4 pg/ml, p<0.05) and MCP-1 (199±5 vs 184±6 pg/ml, p<0.05), as well as a significant increase in ratio IL-10/TNF-a (1.9±0.3 vs 3.5±0.9, p<0.05), IL-10/IL-6 (2.6±0.6 vs 3.5±0.5, p<0.05) and TGF-b2/TNF-a (3.1±0.6 vs 4.4±0.6, p=0.05) were observed in IDC patients after GH treatment. A significant reduction in LV end-systolic volume index (LVESVI, 128±12 vs 102±12 ml/m2, p<0.01) and LV end-diastolic volume index (LVEDVI, 228±16 vs 200±14 ml/m2, p<0.05), as well as a significant increase in posterior wall thickness (PWTH, 9.2±0.5 vs 10.3±0.6 mm, p<0.05) and VO2max (15.3±0.7 vs 17.1±0.9 ml/kg/min, p<0.05) were also found. A good correlation was found between GH-induced reverse LV remodeling expressed by the percentage reduction of LVESVI and percentage increase in exercise tolerance expressed by VO2max (r= -0.53, p=0.05). Finally, GH-induced reduction in LVESVI was significantly correlated with respective increase of plasma IL-10/TNF-a ratio (r=0.62, p<0.01). Conclusions: GH administration modulates beneficially circulating cytokine balance and causes reverse LV remodeling in patients with CHF and IDC. Immunoregulatory effects of GH may be associated with the improvement of exercise capacity and LV geometry of IDC patients. 
